JZL-195

JZL-195 is a drug that acts as a potent and selective inhibitor of the enzymes FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase), which are responsible for the degradation of the endocannabinoids anandamide and 2-AG respectively. This gives it a unique profile of action that is different from other cannabinoid reuptake inhibitors or synthetic cannabinoid agonists.

Pharmacology

JZL-195 is a potent and selective dual inhibitor of FAAH and MAGL, the primary enzymes responsible for endocannabinoid degradation. By inhibiting these enzymes, JZL-195 effectively increases the concentration of endocannabinoids in the brain, leading to enhanced cannabinoid receptor activity.

Therapeutic Potential

The therapeutic potential of JZL-195 is currently being investigated. Preclinical studies have suggested that it may have potential in the treatment of pain, anxiety, depression, and neurodegenerative disorders. However, further research is needed to fully understand its therapeutic potential and safety profile.

Side Effects

As with all drugs, JZL-195 has the potential to cause side effects. These may include dizziness, dry mouth, and changes in appetite. However, the side effect profile of JZL-195 is not fully understood, and further research is needed.

See Also

• Endocannabinoid system
• Cannabinoid receptor
• FAAH
• MAGL

JZL-195 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski